My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

24.21 -0.07 (-0.29%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

November 21, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report ↗

November 19, 2025

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Via Benzinga

Topics Law Enforcement

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

November 19, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 ↗

November 11, 2025

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.

Via The Motley Fool

Topics Artificial Intelligence

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

November 10, 2025

Via Benzinga

Price Over Earnings Overview: Teva Pharmaceutical Indus ↗

November 10, 2025

Via Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗

November 09, 2025

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Via Benzinga

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

November 07, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Why Teva Pharmaceutical Stock Rocked the Market Today ↗

November 05, 2025

The company delivered a convincing pair of beats in its third-quarter earnings report.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook ↗

November 05, 2025

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.

Via Benzinga

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...

Via MarketMinute

Topics Economy Intellectual Property Supply Chain

Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike ↗

November 05, 2025

Teva stock jumped Wednesday on better-than-expected quarterly metrics.

Via Investor's Business Daily

Topics Earnings

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

November 05, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock ↗

November 03, 2025

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock

Via The Motley Fool

Topics ETFs Economy Regulatory Compliance

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally ↗

November 03, 2025

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally

Via The Motley Fool

Topics Artificial Intelligence

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

November 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

October 31, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares ↗

October 29, 2025

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares

Via The Motley Fool

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

October 20, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

October 13, 2025

Druckenmiller is considered one of the best investors of all time.

Via The Motley Fool

Topics Artificial Intelligence Economy

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

October 10, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

SciSparc And AutoMax Call Off Merger ↗

October 06, 2025

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters ↗

October 06, 2025

Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.